Tag: Sickle-Cell Anemia
Many Children With Sickle Cell Anemia Do Not Meet Quality Indicators
Rates of receipt of recommended antibiotic prophylaxis and annual transcranial Doppler low
Gene Therapy for Sickle Cell Disease Likely Cost-Effective at <$2 Million
Incremental cost-effectiveness ratios were $126,000 and $281,000 per QALY for two simulation models from a societal perspective
COVID-19 Vaccine Uptake Lagging in Patients With Sickle Cell Disease
In Michigan, those with sickle cell disease have half the coverage rate of people without sickle cell disease
First Gene-Editing Therapies for Sickle Cell Disease Approved by FDA
In both therapies, stem cells are removed from a patient's blood for treatment
Disease-Modifying Therapy Use for Sickle Cell Remained Low 2014 to 2021
Inconsistent users of DMT had higher prevalence of vaso-occlusive crises, splenic complications, health care visits
AAO: Research Highlights Vision Issues Seen in Pediatric Sickle Cell Disease
Study shows 33 percent have nonproliferative retinopathy and 6 percent have proliferative retinopathy
FDA Advisors Say New Gene Therapy for Sickle Cell Disease Is Safe
Decision clears the way for full approval of the treatment by early December
FDA Advisers to Weigh New Gene Therapies for Sickle Cell Anemia
Advisers will consider whether more research is needed into potential unintended consequences of the new therapies
Pneumococcal Infection Reduced in Children With Sickle Cell Since PCV13
After 2010, all invasive pneumococcal infection serotypes were those not included in 13-valent pneumococcal conjugate vaccine
Sickle Cell Disease Highly Contributes to All-Cause Mortality
Global sickle cell disease mortality burden was 376,000 in 2021; 81,100 deaths reported in children younger than 5 years
